NO20024679L - Krystallinsk farmasöytikum - Google Patents

Krystallinsk farmasöytikum

Info

Publication number
NO20024679L
NO20024679L NO20024679A NO20024679A NO20024679L NO 20024679 L NO20024679 L NO 20024679L NO 20024679 A NO20024679 A NO 20024679A NO 20024679 A NO20024679 A NO 20024679A NO 20024679 L NO20024679 L NO 20024679L
Authority
NO
Norway
Prior art keywords
pharmaceuticals
crystalline
crystalline pharmaceuticals
Prior art date
Application number
NO20024679A
Other languages
English (en)
Other versions
NO20024679D0 (no
NO325005B1 (no
Inventor
Daniel A Dickman
Sanjay Chemburkar
James J Fort
Rodger F Henry
David Lechuga-Ballesteros
Yuping Niu
William Porter
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27065762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024679(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/793,536 external-priority patent/US6608198B2/en
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of NO20024679D0 publication Critical patent/NO20024679D0/no
Publication of NO20024679L publication Critical patent/NO20024679L/no
Publication of NO325005B1 publication Critical patent/NO325005B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024679A 2000-03-30 2002-09-30 Krystallinske former av lopinavir, farmasoytiske sammensetninger omfattende disse og deres anvendelse NO325005B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53825700A 2000-03-30 2000-03-30
US09/793,536 US6608198B2 (en) 2000-03-30 2001-02-27 Crystalline pharmaceutical
PCT/US2001/009112 WO2001074787A2 (en) 2000-03-30 2001-03-21 Crystalline pharmaceutical

Publications (3)

Publication Number Publication Date
NO20024679D0 NO20024679D0 (no) 2002-09-30
NO20024679L true NO20024679L (no) 2002-09-30
NO325005B1 NO325005B1 (no) 2008-01-14

Family

ID=27065762

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024679A NO325005B1 (no) 2000-03-30 2002-09-30 Krystallinske former av lopinavir, farmasoytiske sammensetninger omfattende disse og deres anvendelse

Country Status (22)

Country Link
EP (1) EP1268442A2 (no)
JP (1) JP2003529592A (no)
KR (1) KR100773258B1 (no)
CN (2) CN101066952A (no)
AR (2) AR033360A1 (no)
AU (3) AU5092001A (no)
BG (1) BG107165A (no)
BR (1) BR0109433A (no)
CA (1) CA2403635A1 (no)
CZ (1) CZ20023529A3 (no)
HU (1) HUP0302675A3 (no)
IL (1) IL151551A0 (no)
MX (1) MXPA02009559A (no)
MY (1) MY128296A (no)
NO (1) NO325005B1 (no)
NZ (1) NZ521183A (no)
PE (1) PE20011232A1 (no)
PL (1) PL359727A1 (no)
SA (2) SA06270303B1 (no)
SK (1) SK14832002A3 (no)
TW (1) TWI284640B (no)
WO (1) WO2001074787A2 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608198B2 (en) 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8445506B2 (en) 2009-02-06 2013-05-21 Hetero Research Foundation Polymorphs of lopinavir
US8637449B2 (en) * 2009-08-27 2014-01-28 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
CN112830899A (zh) * 2021-01-18 2021-05-25 合肥华方医药科技有限公司 一种洛匹那韦新晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound

Also Published As

Publication number Publication date
SA01220270B1 (ar) 2006-11-14
IL151551A0 (en) 2003-04-10
AU5092001A (en) 2001-10-15
CA2403635A1 (en) 2001-10-11
SK14832002A3 (sk) 2003-02-04
BG107165A (bg) 2003-07-31
KR20030011807A (ko) 2003-02-11
AR033360A1 (es) 2003-12-17
NO20024679D0 (no) 2002-09-30
TWI284640B (en) 2007-08-01
AU2001250920B2 (en) 2006-06-29
PL359727A1 (en) 2004-09-06
EP1268442A2 (en) 2003-01-02
NO325005B1 (no) 2008-01-14
AR049560A2 (es) 2006-08-16
HUP0302675A2 (hu) 2003-12-29
JP2003529592A (ja) 2003-10-07
MY128296A (en) 2007-01-31
CN1330639C (zh) 2007-08-08
PE20011232A1 (es) 2001-12-08
SA06270303B1 (ar) 2009-08-02
NZ521183A (en) 2004-03-26
BR0109433A (pt) 2004-08-10
WO2001074787A2 (en) 2001-10-11
CN101066952A (zh) 2007-11-07
KR100773258B1 (ko) 2007-11-05
WO2001074787A3 (en) 2002-02-07
MXPA02009559A (es) 2003-05-21
AU2006222711A1 (en) 2006-10-19
CZ20023529A3 (cs) 2003-02-12
CN1422259A (zh) 2003-06-04
HUP0302675A3 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
NO20003967D0 (no) Farmasøytiske preparater
NO20026196L (no) Kinazolinditosylatsalt-forbindelser
DK1226127T3 (da) Substituerede phenylsulfamoylcarboxamider
DK1619192T3 (da) Arylkondeserede azapolycykliske forbindelser
DE60114153D1 (de) Substituierte arylpyrazine
AR028393A1 (es) Iminoazidas substituidas
NO20020030D0 (no) Krystallinske 1-metylcarbapenemforbindelser
DK1331972T3 (da) Farmaceutiske præparater
AR028302A1 (es) Feniluracilos substituidos
IT250181Y1 (it) Custodia perfezionata per rivoltella
DE60130137D1 (de) Kristallisationsverfahren
DE50112662D1 (de) Substituierte benzoylcyclohexenone
ID29755A (id) Senyawa-senyawa organosilikon
ATE372338T1 (de) Deshalogenverbindungen
NO20023508D0 (no) Kalsilyttiske forbindelser
NO20030303L (no) Kalsilytiske forbindelser
NO20031837D0 (no) Kalsilytiske forbindelser
TR200100070A3 (tr) Bilesim
NO20024679L (no) Krystallinsk farmasöytikum
EE200300045A (et) Kristalne ravimaine
SE0001422D0 (sv) Crystalline form
SE0001187D0 (sv) Crystalline form
DE50104937D1 (de) Konfigurationseinheit
SE9904417D0 (sv) Crystalline form
SE9902939D0 (sv) Pharmaceuticals

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application